Biomea Fusion, Inc.
BMEANasdaq
$1.28
↑ +1.6%Jul 17 close · end-of-day
Price
1Y↓ -33.0%
End-of-day closes; the latest point is the live 15-min-delayed price · split & dividend adjusted · chart by TradingView
Key statistics
Market Cap
$92.5M
Enterprise Value
$47.9M
P/E
—
P/S
—
P/B
4.9
EV/EBITDA
—
PEG
—
FCF Yield
—
Dividend Yield
—
Revenue (TTM)
—
Net Income (TTM)
-$45.0M
Free Cash Flow (TTM)
—
Gross Margin
—
Operating Margin
—
Net Margin
—
ROE
-240.1%
ROIC
—
Debt / Equity
—
Net Cash
$44.7M
Return 1Y
-31.9%
Company profile
Biomea Fusion, Inc. focuses on the discovery and development of irreversible small molecules to treat patients with genetically defined cancers and metabolic diseases. BMF-219, an orally bioavailable, potent, and selective irreversible inhibitor of menin, a transcriptional regulator in oncogenic signaling in multiple cancers.
- CEO
- Thomas Butler
- Sector
- Manufacturing
- Industry
- Pharmaceutical Products
- Employees
- 50
- Headquarters
- California
- Website
- biomeafusion.com
Management & directors
- Erdtmann Rainer MSee Remarks
- Hitchcock Michael J.M.Interim CEO
Roles derived from SEC Form 4 filings.
Earnings
BMEA Q1 2026 Earnings
Period ends 2026-03-31
MetricActualYoY
Revenue——
Diluted EPS-$0.17↓ -78.8%
Actuals from SEC filings; YoY vs the year-ago quarter. Analyst estimates & surprise require a data feed (coming soon).
Financial statements
| Line item | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|
| Revenue | — | — | — | — | — | — |
| Gross profit | — | — | — | — | — | — |
| Operating income | -$5.3M | -$41.7M | -$83.6M | -$126.1M | -$144.1M | -$83.5M |
| Net income | -$5.3M | -$41.6M | -$81.8M | -$117.3M | -$138.4M | -$61.8M |
| Diluted EPS | -$0.51 | -$1.74 | -$2.80 | -$3.44 | -$3.83 | -$1.18 |
| Operating cash flow | -$4.5M | -$35.4M | -$62.4M | -$96.6M | -$119.9M | -$70.4M |
| Free cash flow | -$4.5M | -$38.6M | -$63.4M | -$100.0M | -$120.3M | — |
| Gross margin | — | — | — | — | — | — |
| Operating margin | — | — | — | — | — | — |
| Net margin | — | — | — | — | — | — |
| Line item | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 |
|---|---|---|---|---|---|---|---|---|
| Revenue | — | — | — | — | — | — | — | — |
| Gross profit | — | — | — | — | — | — | — | — |
| Operating income | -$38.9M | -$34.0M | -$30.1M | -$29.7M | -$21.3M | -$20.8M | -$11.7M | -$12.8M |
| Net income | -$37.3M | -$32.8M | -$29.3M | -$29.3M | -$20.7M | -$16.4M | $4.6M | -$12.4M |
| Diluted EPS | -$1.03 | -$0.91 | -$0.81 | -$0.80 | -$0.51 | -$0.27 | $0.40 | -$0.17 |
| Operating cash flow | -$32.6M | -$25.2M | -$30.0M | -$25.7M | -$19.2M | -$11.6M | -$13.9M | -$11.7M |
| Free cash flow | -$32.7M | -$25.4M | -$30.1M | -$25.7M | -$19.2M | -$11.6M | — | — |
| Gross margin | — | — | — | — | — | — | — | — |
| Operating margin | — | — | — | — | — | — | — | — |
| Net margin | — | — | — | — | — | — | — | — |
Company news
May 11, 2026
Analyst estimates
Coming soonConsensus revenue & EPS estimates and price targets will appear here once a forward-estimates data feed is connected.
Insider transactions
BoughtSoldMonthly insider $ volume · trailing 12 months
| Date | Insider | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| 2025-12-11 | Erdtmann Rainer M· See Remarks | Buy | 30,000 | $1.43 | $42,999.00 | filing |
| 2025-12-02 | Hitchcock Michael J.M.· Interim CEO | Buy | 100,000 | $0.99 | $99,180.00 | filing |
| 2025-12-01 | Erdtmann Rainer M· See Remarks | Buy | 10,000 | $1.05 | $10,500.00 | filing |
| 2025-11-28 | Erdtmann Rainer M· See Remarks | Buy | 40,000 | $1.10 | $44,052.00 | filing |
Latest 4 transactions.
Fundamentals & filings from SEC EDGAR. Prices adjusted for splits & dividends. Not investment advice.